MedTrace Logo

Retrospective Analysis of Patients With Metastatic Renal Cell Carcinoma Treated With CABOzantinib

NCT06548867 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2024-08-12

No results posted yet for this study

Summary

CABOGEN is a Observational, retrospective, multicenter study that will enroll patients with metastatic clear cell renal carcinoma (mccRCC) treated with cabozantinib after one or more previous lines of treatment that included TKIs, immune checkpoint inhibitors or mTOR inhibitors.

Conditions

  • Metastatic Renal Cell Carcinoma

Interventions

DRUG

Cabozantinib

Patients must have been treated with cabozantinib after one or more previous therapies for mRCC, as per clinical practise.

Sponsors & Collaborators

  • Yghea

    collaborator UNKNOWN

  • Ipsen

    collaborator INDUSTRY

  • Gruppo Oncologico Italiano di Ricerca Clinica

    lead OTHER

Principal Investigators

  • Carmine Pinto, MD · AUSL/IRCCS of Reggio Emilia

  • Cristina Masini, MD · AUSL/IRCCS of Reggio Emilia

  • Stefania Di Girolamo, MD · AUSL/IRCCS of Reggio Emilia

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-28
Primary Completion
2025-06-30
Completion
2025-06-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06548867 on ClinicalTrials.gov